BHC Share Price | Bausch Health Cos., Inc. Stock Analysis & Recommendation

Q: What does Bausch Health Cos., Inc. do?

Overview:Bausch Health Companies Inc. is a Canada-based company that develops, manufactures, and markets a range of branded and generic pharmaceuticals, medical devices, and over-the-counter products in the Pharmaceuticals & Biotechnology industry, with a market cap of CAD 3,900.28 Million.Financial Snapshot:Market cap: CAD 3,900.28 Million (Mid Cap)Key Metrics:P/E: 13.00Dividend Yield: 0.00%Debt Equity: -18.35Return on Equity: 1.10%Price to Book: -3.31Contact Details:Address: 2150 Saint-Elzear Blvd W, LAVAL QC: H7L 4A8Tel: ['1 514 7446792', '1 949 4616002']Fax: 1 514 7446272Website: https://www.bauschhealth.com/

Q: Is Bausch Health Cos., Inc. technically bullish or bearish?

As of 1 October 2023, the technical stance for Bausch Health Cos., Inc. is currently neutral with a mildly bearish strength. The weekly MACD indicates a mildly bullish sentiment, while the monthly MACD is bearish. The Bollinger Bands show a mildly bullish trend on the weekly chart but a mildly bearish trend on the monthly chart. Daily moving averages are mildly bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory reflects a no trend on the weekly chart and mildly bullish on the monthly chart. Overall, the mixed signals across different time frames suggest a lack of clear direction.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

345.89 k

Shareholding (Sep 2025)

FII

54.49%

Held by 403 FIIs

DII

33.2%

Held by 32 DIIs

Promoter

9.44%

What does Bausch Health Cos., Inc. do?

22-Jun-2025

Bausch Health Companies Inc. is a Canadian firm that develops, manufactures, and markets branded and generic pharmaceuticals, medical devices, and over-the-counter products, with a market cap of CAD 3,900.28 million. Key financial metrics include a P/E ratio of 13.00 and a return on equity of 1.10%.

View full answer

Who are in the management team of Bausch Health Cos., Inc.?

22-Jun-2025

As of March 2022, the management team of Bausch Health Cos., Inc. includes Mr. Joseph Papa as Chairman and CEO, and Mr. Thomas Ross as Lead Independent Director, along with independent directors Mr. Richard De Schutter, Mr. D. Robert Hale, Dr. Argeris Karabelas, and Ms. Sarah Kavanagh.

View full answer

Is Bausch Health Cos., Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, Bausch Health Cos., Inc. shows a neutral technical stance with mixed signals, indicating mildly bearish strength on daily and monthly charts, while weekly indicators suggest a mildly bullish trend.

View full answer

Compare Bausch Health Cos., Inc. with Similar Stocks

MoonLake Immunotherapeutics Amicus Therapeutics, Inc.Cerevel Therapeutics Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 3,900 Million ()

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-18.35

Return on Equity

1.10%

Price to Book

-3.31

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

24.42%

6 Months

6.58%

1 Year

23.57%

2 Years

-66.83%

3 Years

-61.35%

4 Years

-67.2%

5 Years

-59.9%

Bausch Health Cos., Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

0.95

Debt to EBITDA (avg)

7.08

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.39

Tax Ratio

31.62%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

75.63%

ROCE (avg)

6.50%

ROE (avg)

20.29%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 17 Schemes (2.87%)

Foreign Institutions

Held by 403 Foreign Institutions (54.49%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.00

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.00

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

All Annual Results

Company CV

About Bausch Health Cos., Inc.

Bausch Health Cos., Inc.

Pharmaceuticals & Biotechnology

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.

Company Coordinates

Company Details

2150 Saint-Elzear Blvd W , LAVAL QC : H7L 4A8

Tel: 1 514 74467921 949 4616002

https://www.bauschhealth.com/

Registrar Details

Bausch Health Cos., Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Bausch Health Cos., Inc. do?

Watch in Real-Time

Who are in the management team of Bausch Health Cos., Inc.?

Is Bausch Health Cos., Inc. technically bullish or bearish?

Compare Bausch Health Cos., Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Bausch Health Cos., Inc.

Company Coordinates